Gain Therapeutics Stock Probability Of Bankruptcy
| GANX Stock | USD 3.19 0.20 5.90% |
Gain | Probability Of Bankruptcy |
Gain Therapeutics Company probability of bankruptcy Analysis
Gain Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Gain Therapeutics Probability Of Bankruptcy | Less than 24% |
Most of Gain Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gain Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Gain Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Gain Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Gain Therapeutics financial health.
Is Gain Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.004 | Quarterly Revenue Growth (1.00) | Return On Assets (0.65) | Return On Equity (1.42) |
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Gain Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Gain Therapeutics is extremely important. It helps to project a fair market value of Gain Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Gain Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gain Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gain Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Gain Therapeutics has a Probability Of Bankruptcy of 24.0%. This is 44.56% lower than that of the Biotechnology sector and 56.24% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 39.74% higher than that of the company.
Gain Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gain Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gain Therapeutics could also be used in its relative valuation, which is a method of valuing Gain Therapeutics by comparing valuation metrics of similar companies.Gain Therapeutics is currently under evaluation in probability of bankruptcy category among related companies.
Gain Therapeutics Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Current Liabilities | 879.1K | 2.1M | 2.6M | 4.1M | 4.9M | 2.8M | |
| Total Current Assets | 429.5K | 9.0M | 37.7M | 21.1M | 17.8M | 15.9M | |
| Total Cash From Operating Activities | (1.9M) | (3.2M) | (12.4M) | (14.7M) | (18.9M) | (17.9M) |
Gain Fundamentals
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.65 | ||||
| Operating Margin | (403.37) % | ||||
| Current Valuation | 39.22 M | ||||
| Shares Outstanding | 16.22 M | ||||
| Shares Owned By Insiders | 16.45 % | ||||
| Shares Owned By Institutions | 11.79 % | ||||
| Number Of Shares Shorted | 138.13 K | ||||
| Price To Book | 4.00 X | ||||
| Price To Sales | 925.92 X | ||||
| Revenue | 55.18 K | ||||
| Gross Profit | (7.66 M) | ||||
| EBITDA | (22.17 M) | ||||
| Net Income | (22.27 M) | ||||
| Cash And Equivalents | 24.25 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.58 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (18.87 M) | ||||
| Short Ratio | 0.94 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Target Price | 8.8 | ||||
| Number Of Employees | 29 | ||||
| Beta | 0.43 | ||||
| Market Capitalization | 54.98 M | ||||
| Total Asset | 18.61 M | ||||
| Retained Earnings | (60.78 M) | ||||
| Working Capital | 12.83 M | ||||
| Net Asset | 18.61 M |
About Gain Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gain Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gain Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gain Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Gain Therapeutics Piotroski F Score and Gain Therapeutics Altman Z Score analysis. For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Gain Stock analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Gain Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.004 | Quarterly Revenue Growth (1.00) | Return On Assets (0.65) | Return On Equity (1.42) |
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.